Next Article in Journal
Bactericidal Pectin/Chitosan/Glycerol Films for Food Pack Coatings: A Critical Viewpoint
Next Article in Special Issue
Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine
Previous Article in Journal
Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer’s Disease
Previous Article in Special Issue
Umbilical Cord-Derived CD362+ Mesenchymal Stromal Cells Attenuate Polymicrobial Sepsis Induced by Caecal Ligation and Puncture
Review

Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies

IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(22), 8662; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21228662
Received: 21 October 2020 / Revised: 13 November 2020 / Accepted: 15 November 2020 / Published: 17 November 2020
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. Nowadays, available therapies for MS can help to manage MS course and symptoms, but new therapeutic approaches are required. Stem cell therapy using mesenchymal stem cells (MSCs) appeared promising in different neurodegenerative conditions, thanks to their beneficial capacities, including the immunomodulation ability, and to their secretome. The secretome is represented by growth factors, cytokines, and extracellular vesicles (EVs) released by MSCs. In this review, we focused on studies performed on in vivo MS models involving the administration of MSCs and on clinical trials evaluating MSCs administration. Experimental models of MS evidenced that MSCs were able to reduce inflammatory cell infiltration and disease score. Moreover, MSCs engineered to express different genes, preconditioned with different compounds, differentiated or in combination with other compounds also exerted beneficial actions in MS models, in some cases also superior to native MSCs. Secretome, both conditioned medium and EVs, also showed protective effects in MS models and appeared promising to develop new approaches. Clinical trials highlighted the safety and feasibility of MSC administration and reported some improvements, but other trials using larger cohorts of patients are needed. View Full-Text
Keywords: multiple sclerosis; mesenchymal stem cells; preclinical models; clinical trials multiple sclerosis; mesenchymal stem cells; preclinical models; clinical trials
Show Figures

Figure 1

MDPI and ACS Style

Gugliandolo, A.; Bramanti, P.; Mazzon, E. Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies. Int. J. Mol. Sci. 2020, 21, 8662. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21228662

AMA Style

Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies. International Journal of Molecular Sciences. 2020; 21(22):8662. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21228662

Chicago/Turabian Style

Gugliandolo, Agnese; Bramanti, Placido; Mazzon, Emanuela. 2020. "Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies" Int. J. Mol. Sci. 21, no. 22: 8662. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21228662

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop